Ora Showcases Cutting-Edge AI and Tech Innovations at ARVO 2025 to Advance Ophthalmology Clinical Trials

Ora, a global leader in ophthalmology contract research, has unveiled several groundbreaking innovations at the 2025 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) held in Salt Lake City, Utah, from May 4 to 8. The company's participation is marked by two podium presentations and ten poster presentations, each highlighting significant advancements in clinical trial methodologies and technologies. CEO Paul Colvin emphasized Ora's commitment to excellence and innovation, noting that the company has contributed to over 85 product approvals in the last five decades. "Our paper and poster presentations at ARVO reflect the passion, excellence, and meaningful impact of our work, aiming to transform patient outcomes," he stated. Among the notable presentations, Keith Lane presented "Automated Optokinetic Nystagmus Testing as an Objective Measure of Visual Acuity in Low Vision Populations" on May 4 from 1:00 PM to 2:45 PM (Presentation/Poster #547-A0108). This research introduces an automated technique to test visual acuity in individuals with low vision, offering a reliable and objective method to assess treatment efficacy. On May 5, Palak Gupta introduced "A Hybrid Machine Learning Pipeline for Real-Time Automated Tracking of Patient Drop Compliance" from 8:30 AM to 10:15 AM (Presentation/Poster #1577-A0499). This presentation focuses on a machine learning system that monitors patient adherence to eye drop regimens in real-time, enhancing data integrity and clinical trial efficiency. Paul Gomes presented "In-Vivo Confocal Microscopy of the Limbus Compared to Lissamine Green Staining Following Exposure to Controlled Adverse Environment" on May 5 from 3:00 PM to 4:45 PM (Presentation/Poster #1979-A0077). The study compares confocal microscopy and traditional staining methods to evaluate ocular surface damage, providing a more detailed and accurate assessment of treatment effects. Ethan Bensinger presented "Personalized Airflow Modulation in a Controlled Adverse Environment for Evaluating Ocular Surface Protection Mechanisms in Dry Eye Simulation" on May 5 from 8:30 AM to 10:15 AM (Presentation/Poster #1600-A0522). This research explores a new model that simulates dry eye conditions by modulating airflow, allowing for more precise and personalized assessment of ocular surface protection mechanisms. Rob Whitfield discussed "Defining Drug Delivery Device Performance of Ophthalmic Blow-Fill-Seal (BFS) Ampoule Based Upon Physical Characteristics" on May 5 from 8:30 AM to 10:15 AM (Presentation/Poster #1571-A0493). The presentation delves into the performance and reliability of BFS ampoules, which are critical for consistent and safe drug delivery in ophthalmic treatments. Palak Gupta returned on May 7 from 2:00 PM to 3:45 PM to discuss "Early Detection of Diabetic Maculopathy with Vanishing Optotypes" (Presentation/Poster #4741-A0067). This method uses specialized optotypes that disappear under certain conditions to detect diabetic maculopathy early, potentially improving treatment outcomes and patient care. Ethan Bensinger presented "Interblink Visual Acuity Decay with Automated Blink Detection in Dry Eye Disease" on May 7 from 11:15 AM to 11:30 AM (Paper Session 4050, Ballroom C). The research examines how visual acuity changes during the interblink period in patients with dry eye disease, providing valuable insights into the condition's natural progression and potential treatment targets. Gus De Moraes discussed "Categorization of Supraciliary Flow Assessed by Ultrasonic Biomicroscopy after Cilioscleral Interposition Device Implantation and its Relationship with Intraocular Pressure" on May 7 from 11:45 AM to 12:00 PM (Paper Session 4076, Ballroom G). This study explores the relationship between supraciliary flow and intraocular pressure, offering a deeper understanding of how implant devices affect these parameters. Gus De Moraes also presented "Advancing Compliance and Data Integrity in Clinical Trials: The Ora Digital Diaries System" on May 8 from 8:00 AM to 9:45 AM (Presentation/Poster #5778-B0374). The digital diaries system aims to improve patient compliance and data integrity, addressing common challenges in clinical trials. Ethan Bensinger shared "Automated Detection and Classification of Limbal Lissamine Green Staining in Dry Eye Subjects Using a Novel Machine Learning Approach" on May 8 from 8:00 AM to 9:45 AM (Presentation/Poster #5638-B0033). This machine learning approach automates the detection and classification of limbal staining, enhancing the precision and consistency of dry eye assessments. Matt Chapin presented "CAE-HT: A Rapid and Precise Challenge Model for Dry Eye Assessment" on May 8 from 8:00 AM to 9:45 AM (Presentation/Poster #5651-B0046). The CAE-HT model provides a rapid and reliable method to simulate dry eye conditions, facilitating more efficient and accurate clinical evaluations. George Ousler's presentation, "Efficacy and Safety of PL9643 in Participants with Dry Eye Disease: Results from a Phase 3, Randomized, Vehicle-Controlled Study," on May 8 from 8:00 AM to 9:45 AM (Presentation/Poster #5667-B0062), detailed the results of a phase 3 study on PL9643, demonstrating its effectiveness and safety in treating dry eye disease. Visitors to Ora's booth (#1701) can explore the convergence of science, strategy, and innovation in ophthalmic clinical trials. The new tagline, "The Ophthalmology Research Company," underscores Ora's dedicated focus on advancing ophthalmic research. Additionally, the booth features "The Blind Canvas Project," a collaboration with BlindCAN, which offers a unique perspective on the human experience of blindness. Industry experts highly commend Ora's contributions to the field, particularly noting the company's pioneering efforts in integrating AI and machine learning into clinical trial methodologies. These innovations not only enhance the accuracy and reliability of data but also accelerate the development and approval of new ophthalmic treatments, ultimately benefiting patients globally. Ora's longstanding reputation as a trusted CRO for both startups and major pharmaceutical companies is further solidified by these advancements. For more information, visit www.oraclinical.com or follow Ora on LinkedIn.